BEBT-260

BEBT-260

   BEBT-260 is a potent inhibitor of Chk1 inhibitor with a novel structure that the company owns global IP rights. Most cancer cells have dysregulated G1 checkpoints (i.e. p53 mutations), making them dependent on the S and G2 checkpoints. Chk1 is a key protein involved in promoting cell cycle arrest and DNA repair after chemo- or radiation. By contrast, normal cells have intact G1 checkpoint and are thus less dependent on S and G2 checkpoints. BEBT-260 treatment in combination with chemotherapeutics showed pronounced synergistic effects in various p53-deficient tumors, including colon, breast, prostate and leukemia, in preclinical experiments.